Duloxetine, a centrally acting analgesic, in the treatment of patients with osteoarthritis knee pain: A 13-week, randomized, placebo-controlled trial

Amy S. Chappell, Melissa J. Ossanna, Hong Liu-Seifert, Smriti Iyengar, Vladimir Skljarevski, Linda Chunhong Li, Robert M. Bennett, Harry Collins

Research output: Contribution to journalArticlepeer-review

192 Scopus citations

Abstract

Pain is a common cause of disability in osteoarthritis. Duloxetine, a serotonin and norepinephrine reuptake inhibitor (SNRI), has demonstrated analgesic effects in diabetic peripheral neuropathy and fibromyalgia. Considering its central mechanism of action, duloxetine may be effective in other pain states with evidence of central sensitization. Herein, we report the results of a 13-week, randomized, double-blind, placebo-controlled trial of duloxetine (60-120 mg/day) versus placebo in the treatment of knee pain in 231 patients meeting clinical and radiographic criteria for osteoarthritis of the knee. Duloxetine was superior to placebo on the primary efficacy measure (weekly mean 24-h pain scores) beginning at Week 1 and continuing through the treatment period (P ≤ .05). There was also a significant improvement in the WOMAC physical functioning subscale and several other secondary outcomes. Adverse-event rates did not differ significantly between treatment groups (49.5% for duloxetine 60-120 mg/day, and 40.8% for placebo).

Original languageEnglish (US)
Pages (from-to)253-260
Number of pages8
JournalPain
Volume146
Issue number3
DOIs
StatePublished - Dec 5 2009
Externally publishedYes

Keywords

  • Duloxetine
  • Osteoarthritis
  • Pain

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology
  • Anesthesiology and Pain Medicine

Fingerprint

Dive into the research topics of 'Duloxetine, a centrally acting analgesic, in the treatment of patients with osteoarthritis knee pain: A 13-week, randomized, placebo-controlled trial'. Together they form a unique fingerprint.

Cite this